Activation of TLR3, TLR4, and TLR9 has been reported to reinforce the antitumor response to anti-PD-1/PD-L1 and exhibit immune checkpoint delayed resistance in glioma cells or animal models [187, 188, 190]. This evidence concerns the gene TLR9 and central nervous system cancer.